
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion for Protalix BioTherapeutics, Inc.’s (NYSE:PLX) and Chiesi Group’s partnered Elfabrio’s revised dosing schedule for Fabry disease.
- PLX is encountering selling pressure. Get the market research here